Fosamax Femur Fracture Lawsuit
More lawsuits against Merck & Company

On December 15, 2011, a Fosamax lawsuit was filed against drug makers Merck & Co. (Merck), maker of Fosamax, and GlaxoSmithKline (GSK), maker of Boniva, in the Superior Court of New Jersey alleging that these bisphosphonate medications caused a woman to suffer a femur fracture.

The woman, Reba Inez Patton, and her husband Patrick Patton, claim that the use of Fosamax, used from 2001 until 2006, and Boniva, used from 2006 until 2010, caused her to suffer a low-energy femur fracture in December of 2010. This type of fracture is a rare kind of bone injury which can occur with little or no trauma.

According to the complaint, plaintiffs believe that both Merck and GSK negligently marketed the drugs, which are supposed to strengthen bones, and failed to provide sufficient warnings regarding femur fracture risks.

The attorney representing the couple stated in an interview that “Merck and GlaxoSmithKline negligently marketed these bisphosphonate products, which lack long-term benefits and also pose significant dangers to patients, especially those who have been on the drugs for many years.” He also included that “Neither doctors nor patients were warned by the manufacturers of these horrible femur fractures caused by long-term use of bisphosphonates.”

As a result of the femur fractures, Mrs. Patton suffers severe and permanent injuries which will require ongoing medical care, along with physical and mental pain and suffering.

Mrs. Patton is not the only victim to suffer injuries from use of bisphosphonate medications. Thousands of claims have been brought forth against Merck & Company in particular. Each lawsuit makes similar claims that the drug company failed to properly warn about the side effects associated with long term use of its drug Fosamax.

Fosamax was initially designed to strengthen bones in women diagnosed with osteoporosis. However, in recent months, many claims of adverse Fosamax long term effects have been reported to the Food and Drug Administration (FDA). Merck tries to counter these claims by stating that no adverse effects were noted during their clinical trials.

The next Fosamax hearing is expected to occur in February of 2012.


About the Contributor

Related Posts